1551-P: Baseline Characteristics of Patients in the First Pan-India, Prospective, Longitudinal Study to Assess Management and Outcomes of T2D in Real-World Settings—LANDMARC

Abstract

Background and Aims: LANDMARC (LongitudinAl NationwiDe StuDy On Management And Real World OutComes of Diabetes In India, CTRI/2017/05/008452) is the first prospective, observational, longitudinal study to understand the development of diabetes complications over a 3-year (yr) period in India with high number of sites (450) and a larger cohort of patients. Methods: Adult subjects with T2D treated with ≥2 antihyperglycemic drugs (controlled/uncontrolled on A1c) were enrolled for assessment and baseline characteristics were analyzed using descriptive statistics. Results: Of 6332 enrolled subjects, 6280 were eligible for baseline assessment. Mean (SD) age, BMI, and T2D duration were 52.12 (9.15) yr, 27.21 (4.59) kg/m2, and 8.57 (5.62) yr, respectively. Baseline A1c (n=4613; mean [SD]) was 8.0 (1.6) % and 1331 subjects (29%) hadA1c <7.0%. Mean (SD) FPG (n=5176) and PPG (n=5067) were 142.6 (50.4) mg/dL and 205.2 (71.8) mg/dL, respectively. Approximately 70% of subjects (n=4556) received only oral antihyperglycemic drugs OADs and 1687 subjects received both OADs and injectables (INJ). Biguanides (n=5829, 92.8%) and sulfonylureas (n=4785, 76.2%) were the most frequently prescribed OADs, and majority of subjects (n=2766, 44.3%) were prescribed two OAD classes. The mean (SD) duration (yr) of T2D was shorter in subjects receiving OADs (7.58 [4.88]) than INJ (11.01 [6.69]) or OAD+INJ (11.21 [6.57]). Most of the eligible subjects (n/N=3266/6280) had ≥1 CV risk factors; hypertension (n=2566, 40.9%) and dyslipidemia (n=1619, 25.8%) being most prevalent. Subjects with baseline A1c >7% to ≤8% had higher incidence of hypertension and dyslipidemia than other A1c groups. Neuropathy was the most common complication (n/N=728/6280, 11.6%) followed by nephropathy (n/N=153/6280, 2.44%). Conclusion: These real-world data provide first insights on the epidemiology and treatment landscape of people with T2D in India. Disclosure R. Ghosh: Employee; Self; Sanofi. A.K. Das: None. A. Unnikrishnan: Other Relationship; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddys Laboratories, Eli Lilly and Company, Eris Pharmaceuticals, Ipca Laboratories Ltd., MSD, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Sanofi. S. Kalra: None. H. Thacker: None. Funding Sanofi